image credit: Unsplash

Regeneron Advances Antibody Cocktail into Phase III Trials

Regeneron Pharmaceuticals said today its double-antibody cocktail against COVID-19 is advancing into Phase III studies, less than a month after the start of its first clinical trial, with preliminary data from one study expected to be reported later this summer.

Regeneron said it is proceeding with clinical development of the antibody cocktail after generating a positive review from the Independent Data Monitoring Committee overseeing the Phase I safety study, following an evaluation of data from an initial cohort of 30 hospitalized and non-hospitalized patients with COVID-19. Regeneron launched the safety study in June.

Read More on Genetic Engineering and Biotechnology News